CA
XENE icon

Crewe Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Crewe Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$185 – 1023
2023
Q4 		$185 Buy
+4
New +$141 ﹤0.01% 354

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Crewe Advisors's XENE Position: Q1 2024 in Review

Crewe Advisors sold out of Xenon Pharmaceuticals (XENE) in Q1 2024, closing a stake of 4 shares — an estimated $185 sold.

Crewe Advisors first reported a position in XENE in Q4 2023 and held it in 1 quarter. The position peaked at $185 in Q4 2023. 220 funds tracked by Wall St. Rank hold XENE as of Q1 2024.

  • Crewe Advisors reported no remaining Xenon Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Crewe Advisors sold 4 Xenon Pharmaceuticals shares in Q1 2024, an estimated $185.
  • Crewe Advisors first reported a position in Xenon Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Crewe Advisors's Xenon Pharmaceuticals position peaked at $185 in Q4 2023.
  • 220 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2024.

Based on Crewe Advisors's 13F filing for Q1 2024, filed 14 May 2024.